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Abstract
Increasing evidence has indicated natural transspecies transmission of gammaretroviruses; however, viral-host interactions
after initial xeno-exposure remain poorly understood. Potential association of xenotropic murine leukemia virus-related
virus (XMRV) in patients with prostate cancer and chronic fatigue syndrome has attracted broad interests in this topic.
Although recent studies have indicated that XMRV is unlikely a human pathogen, further understanding of XMRV
xenoinfection would allow in vivo modeling of the initial steps of gammaretroviral interspecies transmission, evolution and
dissemination in a new host population. In this study, we monitored the long-term consequences of XMRV infection and its
possible vertical transmission in a permissive foreign host, wild-derived Mus pahari mice. One year post-infection, XMRV-
infected mice showed no notable pathological changes, while proviral DNA was detected in three out of eight mice. XMRV-
infected mice remained seropositive throughout the study although the levels of gp70 Env- and p30 capsid-specific
antibodies gradually decreased. When vertical XMRV transmission was assessed, no viremia, humoral immune responses nor
endogenization were observed in nine offspring from infected mothers, yet one offspring was found PCR-positive for XMRV-
specific sequences. Amplified viral sequences from the offspring showed several mutations, including one amino acid
deletion in the receptor binding domain of Env SU. Our results therefore demonstrate long-term asymptomatic infection,
low incidence of vertical transmission and limited evolution of XMRV upon transspecies infection of a permissive new host,
Mus pahari.
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Introduction
Gammaretroviruses usually transmit within a single host species
[1,2], often from mother to offspring [3,4]. However, studies have
also identified a number of probable natural interspecies
transmissions between different species of placental mammals,
placental and marsupial mammals, and mammals to birds [5–7].
For instance, recent transspecies transmission and ongoing
endogenization of a gammaretrovirus have been implicated in
koala retrovirus (KoRV), which causes lymphoid neoplasias in
captive and wild koalas [8–10]. Since KoRV is closely related to
gibbon ape leukemia virus and woolly monkey virus [11–13], these
three viruses are considered to be from a common ancestor [8,12],
likely a close relative of an endogenous gammaretrovirus from an
Asian wild mouse [6]. However, the initial steps of gammare-
troviral interspecies transmission, adaptation and dissemination in
a new host population remains poorly understood.
Previously, due to the possible concerns over the potential
zoonotic transmission of endogenous retroviruses, the xenotropic
infection by porcine endogenous retroviruses (PERV) has been
extensively studied in immunocompromised mice or patients
transplanted with pig organs. Those studies found the lack of
evidence for PERV transmission in nonhuman primate models or
humans transplanted or treated with porcine tissues [14–16], while
modest PERV replication was observed in mice transgenic for a
human PERV receptor [17]. The experimental transspecies
transmission of KoRV was also assessed in rats. KoRV was able
to establish a productive infection in all rats at an early stage (3
weeks post infection), while the virus was efficiently cleared in most
animals by 8 weeks. Of note, one KoRV-infected rat developed a
fibrosarcoma with high levels of KoRV proviral DNA [5]. Those
observations demonstrate rather efficient viral clearance upon
artificial xenoinfection of gammaretroviruses.
Murine gammaretroviruses, including exogenous and endoge-
nous murine leukemia viruses (MLVs), were obtained from inbred
mice and feral mice trapped in the wild, and these viruses were
classified into various categories based on the host range and
receptor usage [18–21]. Ecotropic MLVs infect only murine cells,
while amphotropic, polytropic and xenotropic MLVs can infect
non-murine cells. Identification of xenotropic murine leukemia
virus-related virus (XMRV) and MLV-like sequences in patients
with prostate cancer [22] and chronic fatigue syndrome [23,24]
has attracted further interests in the transspecies transmission of
MLV and MLV-related viruses. Although recent studies have
casted the doubt over the authenticity of XMRV and MLV-like
viruses as human pathogens [25–30], understanding of XMRV
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29682infection in a foreign host could provide unique insights into how a
gammaretrovirus replicates, adapts and disseminates in a new host
species. We have previously reported early events in XMRV
infection of an Asian wild mouse species with functional Xpr1
receptor for XMRV entry [31,32,33]. XMRV proviral DNA was
detected in spleen, blood, and brain at five to twelve weeks post-
intraperitoneal infection [33]. Mice infected with XMRV
mounted adaptive immune responses against XMRV as evidenced
by the production of neutralizing antibody for XMRV Env and
Gag [33]. Prominent G-to-A hypermutations were also found in
viral genomes isolated from the spleen, suggesting intracellular
restriction of XMRV infection by APOBEC3 in vivo [33]. XMRV
is also restricted by both Fv1
n and Fv1
b [34]. However Mus pahari
lacks the Fv1 restriction gene because Fv1 was acquired in the Mus
lineage after Mus pahari diverged [35]. These data support the use
of XMRV and Mus pahari as a model for transspecies transmission
of a gammaretrovirus.
In this study, we examined the long-term consequences of
XMRV infection and possible vertical transmission of XMRV
from mother to offspring. Mice infected with XMRV remained
seropositive over one year. At one year post-infection, no notable
pathological changes were observed, while proviral DNA was
detected in three out of eight infected mice. When nine offspring
from XMRV-infected parents were examined, only one offspring
was found positive for XMRV proviral DNA. Our results
therefore demonstrate the long-term control and low incidence
of vertical transmission of XMRV upon transspecies infection of a
permissive foreign host, Mus pahari.
Results and Discussion
We have previously reported on the early events of XMRV
infection in Mus pahari [33]. Using these wild-derived mice, which
have no endogenous MLV-like sequences in its genome and lack
the potent retroviral restricting Fv1 activity [36–38], we examined
the long-term consequences of the virus infection. A total of 8 mice
which showed XMRV seroconversion were used in this study
[29,33]. Plasma samples of these infected mice showed strong
XMRV-neutralizing activity (i.e., 9660.011, 9960.004,
9560.012, 9860.009, and 10060 percent neutralization, at
12 wk, 16 wk, 24 wk and 1 year p.i., respectively, 6 standard
error) at a dilution of 1:20 (Fig. 1A and B). Specificity of these
neutralizing antibodies was further verified by Western blotting
(Fig. 1C); plasma from these mice with high neutralizing activities
could detect XMRV-specific structural proteins, i.e., Env
glycoprotein (gp70), capsid protein (CA; p30), matrix protein
(MA; p15) and transmembrane envelope protein (TM; p15E), over
one year. In general, plasma from infected mice at 12–24 wk p.i.
readily detected all the virus proteins (Fig. 1C), while most plasma
from mice at 1 year p.i. still showed immune reactivity against Env
gp70 and CA p30.
We also examined the biodistribution of XMRV in mice
chronically infected with XMRV. Although we previously
detected XMRV-specific sequences in blood, heart, brain,
prostate, and testis tissues at 2 and 4 wk p.i. [33], XMRV DNA
was not detected from blood or plasma in any mice after 8 wk p.i..
No viral RNA was detected from plasma samples at any time point
tested. We were also unable to isolate XMRV from infected mice
at 8 wk p.i. through co-cultivation of blood cells with 293T cells,
followed by 10 passages. These results suggested the lack of active
viral production after the early stage of viral infection, most likely
due to the sustained XMRV-specific humoral immune response.
In acute XMRV infection, some mice showed increased
numbers of white blood cells (WBC) including lymphocytes,
monocytes, or granulocytes [33]. We therefore monitored the
blood parameters of XMRV-infected mice over one year (Tables
S1, S2, S3, S4, S5). The 95% reference range was calculated as
(mean 21.966SD) to (mean +1.966SD) using CBC data from 12
uninfected Mus pahari as determined previously [33] and used as
indicative values. Of note, one control mouse (6M) had mild
thrombocytosis at early stage of the study (Table S1). The numbers
of WBC and red blood cells (RBC) mostly fit within the normal
range of blood parameters for Mus pahari (normal ranges for WBC
and RBC between 4.4,8.6610
9/L and 9.1,12.1610
12/L,
respectively) [33]. Although transient reduction in numbers of
WBC were observed in two animals at 24 wk p.i. (0.94 and
2.96610
9/L; Table S4) with abnormally low lymphocyte numbers
(i.e., 0.78 and 2.5610
9/L, respectively), these numbers were
returned to normal at 1 year p.i. (Table S5). The lymphocytosis
found in most treated mice cannot be accurately linked to XMRV
infection due to the lack of appropriate age-matched controls.
(Table S4). RBC counts including hemoglobin (HGB) and mean
corpuscular hemoglobin concentration (MCHC) were generally
within normal range at each time point analyzed except for 24 wk
p.i. (Table S4), and the number of RBCs went back to normal at 1
year p.i. (Table S5). In addition, marginal reductions in MCHC
were observed in 6 out of 9 mice at 1 year p.i. (Table S5). When
we analyzed the blood chemistry at 1 year p.i., concentrations of
albumin, alkaline phosphatase, alanine transferase, amylase, blood
urea nitrogen, calcium (not ionized), creatinine, globulin, glucose,
potassium, sodium, phosphorus, total bilirubin, and total protein
were all within normal ranges, indicating that long-term XMRV
infection did not affect the metabolic and hepatic functions, and
renal function did not show a significant pathology.
To analyze the possible pathological abnormalities and the
presence of XMRV proviral DNA, we sacrificed the mice at 1 year
p.i.. Five XMRV infected mice plus one control mouse showed
notable calcification in pancreas, a sign commonly seen in chronic
pancreatitis, while no notable pathological changes was observed
in the other mice. We also tested the presence of XMRV provirus
in the organs including heart, brain, spleen, lung, kidney,
pancreas, bladder, testis, prostate, and lymph node by real-time
qPCR as reported previously [29]. Most samples were negative for
XMRV-specific DNA, including the pancreas with notable
calcification. From the tissues analyzed, three samples were
qPCR-positive (the pancreases from animal P1F and P4F had
150 and 190 genome copies/mg, respectively, and the spleen in
mouse P2F had 30 genome copies/mg). We amplified and
sequenced the env region of XMRV by nested PCR to compare
to a sequence used to infect the mice. Nine mutations, from T to C
(64), G to T (62), G to C (61), A to T (61) and T to G (61) in a
total of 4959 bp (from nucleotide (nt) position 5864 to nt 6414,
based on GenBank accession no. NC_007815) sequenced, and
three mutations, from C to T (62) and A to G (61) in a total of
4408 bp sequenced, were found in the pancreas-derived DNA
from mice P1F and P4F, respectively. Five mutations, from G to A
(62), T to C (61), G to T (61), and C to T (61) in a total of
5510 bp (from nt 5864 to nt 6414 analyzed based on GenBank
accession no. NC_007815) sequenced were found in the spleen of
mouse P2F. These results demonstrated relatively low levels of
genetic mutations in XMRV env gene upon long-term infection,
which is likely due to poor viral replication in this mouse model.
It is well documented that exogenous MLV strains, which share
high sequence similarities with XMRV, are vertically transmitted
from mother to offspring [3,39–42]. In order to examine the
possible vertical transmission of XMRV, offspring that were born
from XMRV-infected mice were included in this study. Three
breeding pairs of Mus pahari mice (Parents: P1 to P3) that produced
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total of nine offspring (Offspring B1 to B3 are from P1, offspring
B4 to B7 are from P2, and offspring B8 and B9 are from P3) were
produced. Using these mice, we first examined if the plasma from
offspring neutralize XMRV. Although plasma samples from
XMRV-infected mothers could completely block XMRV infection
(,100% neutralization, Fig. 1A), none of the offspring showed
strong XMRV neutralizing activities (Fig. 2A). Plasma from these
offspring also failed to detect XMRV structural proteins by
Western blotting (Fig. 2B). These results indicate that offspring did
not receive the maternal immunity against XMRV nor develop
anti-XMRV antibodies.
The lack of anti-XMRV antibodies in the offspring could be
due to no vertical XMRV transmission or due to immunological
tolerance to XMRV antigens in infected offspring. Our attempts
to isolate XMRV from the offspring, through co-cultivation of
offspring blood cells with 293T cells, followed by serial passages
for four weeks, were unsuccessful. We then analyzed the
presence of XMRV-specific proviral DNA in the tissue samples
i n c l u d i n gb r a i n ,h e a r t ,l u n g ,l i v e r ,s p l e e n ,k i d n e y ,l y m p hn o d e ,
bladder, and prostate by real-time qPCR as described previously
[29,33]. XMRV-positive samples were only found from one
offspring, B1 (0.3 and 24 copies of viral genome sequences/mgi n
tissues of lymph node and heart DNA samples, respectively).
Partial env gene was amplified from these tissues, cloned and
sequenced, and the variations in the recovered viral sequences
were determined. We obtained fourteen PCR clones and env
gene from nt 5864 to nt 6414 bp (NC_007815) was sequenced.
All the identified sequences were closely related to XMRV,
rather than exogenous MLV CasE #1, which was previously
detected in Mus pahari [33] or endogenous MLV-like sequences
in laboratory mice. Although sequencing analysis found no
notable G-to-A mutations in the env gene (Fig. 3A), one sequence
from B1 (GenBank accession no. JN987227) showed a deletion
of three nucleotides (Fig. 3B) resulting in a single amino acid
(S148) deletion in the receptor binding domain of the Env SU
region. SU glycoprotein variable regions VRA, VRB, and VRC
(Fig. 3 B) are known to determine receptor specificity [22,43].
However, the deletion mutation fell in a region not known to
influence receptor interactions.
Figure 1. Sustained anti-XMRV humoral immunity in mice chronically infected with XMRV. (A) Neutralization assay was carried out using
GFP-carrying XMRV as described previously [33,52]. Flow cytometry analysis of virus neutralization activities of plasma samples from XMRV-infected
mice (P1F and P2F) is compared to those from a control mouse (6M). (B) Results from neutralization assay are summarized in percentage which was
calculated as the reciprocal of infectivity with a maximum infectivity being determined by incubation of the virus with an uninfected mouse serum.
Data from Parent 1 female (P1F), P1 male (P1M), P2F, P3F, and P3M are shown. (C) XMRV proteins were detected by Western blotting with plasma
samples of XMRV-infected mice. Results from five (P1F, P1M, P2F, P3F, and P3M) mice and a control (p5F) are shown. Viral proteins, envelope, Env
(gp70), capsid, CA (p30), envelope transmembrane, TM (p15E), and matrix, MA (p15) are indicated. XMRV antigen negative and positive are indicated
as 2 and +, respectively. Blood samples were collected at 8 wk, 12 wk, 16 wk, 24 wk and 1 year p.i.
doi:10.1371/journal.pone.0029682.g001
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domain of XMRV Env (Fig. 3C). To address the influence of this
mutation on viral infectivity, we introduced the same mutation
into a retroviral vector system, and examined the effects on
retroviral infectivity. We first verified the expression of the S148-
deleted XMRV Env by Western blotting (Fig. 3C). When
retrovirus vectors with wildtype XMRV Env or the mutated
Env were produced as described previously [44], the vector with
the S148 deletion showed an approximately 10-fold lower titer
than that of wild-type vector (Fig. 3D). This observation
demonstrated that the S148 mutation in the SU region impairs
viral infectivity. We speculate that immune escape from XMRV-
specific antibodies through the S148 deletion mutation impaired
the viral fitness. Alternatively, this mutation was the consequence
of viral adaptation to Mus pahari Xpr1 receptor, rather than
human XPR1. Further study using cell lines expressing Xpr1
variants will address these questions.
Studies of exogenous MLVs in laboratory mice have demon-
strated frequent mother-to-offspring transmission, particularly
through milk [39,45]. For instance, a study using a temperature-
sensitive Moloney murine leukemia virus has demonstrated that
about 39% of transmission occurs in utero (up to day 20 of
gestation) and nearly 100% transmission occurs if the offspring
suckle breast milk from the infected mothers [46]. On the other
hand, reduced vertical transmission is often observed when MLV-
infected mice have circulating antibodies [39,47,48]. Our study
showed inefficient mother-to-offspring XMRV transmission.
Offspring were born from XMRV-infected mothers that had high
levels of circulating anti-XMRV antibodies at the time of delivery.
Thus, low incidence of vertical transmission is likely due to the lack
of chronic viremia in Mus pahari infected with XMRV. Our
attempts to detect XMRV-specific sequences in the milk from
XMRV-infected mother mice were unsuccessful, due to technical
difficulties to harvest milk from lactating mice.
In utero infection or neonatal infection of exogenous MLVs often
results in immunological tolerance, leading to frequent viremia in
newborn mice [3,39–42]. It is notable that 78% of offspring were
viremic in Lake Casitas wild mice that were naturally infected with
an exogenous MLV [41]. In contrast, MLV infection at a late
postnatal stage often results in induction of passive immunity and
asymptomatic infection [49]. In our study, we were unable to
isolate XMRV from blood, or to detect viral RNA in the
circulation (data not shown), indicating no sustained viremic
offspring from XMRV-infected mothers. One offspring was viral
DNA positive, but showed no viremia. Thus, we speculate that this
mouse was infected by XMRV at a late postnatal stage, most likely
through breast milk. The lack of detectable antibodies against
XMRV in this offspring might be due to recent XMRV exposure,
or limited XMRV replication in this mouse.
In summary, we demonstrate that XMRV shows a very limited
replication in a permissive host over a period of one year. We also
showed the possible vertical XMRV transmission from mother to
offspring with a low frequency. No endogenization was observed
in the nine offspring born from XMRV-positive mothers.
Recently, poor replication of XMRV was also reported in
XMRV-infected rhesus monkeys [50]. This may also explain
why transspecies gammaretroviral transmission does not occur
frequently; as it is likely a difficult task for a gammaretrovirus to
overcome both potent retroviral restriction factors, such as




The wild-derived mice, Mus pahari/EiJ, were purchased from
the Jackson Laboratory. The mice were housed in the Mayo Clinic
Animal Facility under the Association for Assessment and
Accreditation of Laboratory Animal Care (AALAC) guidelines
with animal use protocols approved by the Mayo Clinic Animal
Use and Care Committee (IACUC number: A24509). All animal
experiments were carried out according to the provisions of the
Animal Welfare Act, PHS Animal Welfare Policy, the principles of
the NIH Guide for the Care and Use of Laboratory Animals, and
the policies and procedures of Mayo Clinic. A total of 10 mice
received approximately 2.2610
8 genomic copies (3.0610
5 infec-
tious units of XMRV/mouse) of XMRV intraperitoneally at 8 to
12 weeks of age. XMRV infection was confirmed by the
seroconversion as described previously [29,33]. For vertical
transmission analysis, offspring born from XMRV-infected parents
were weaned at 4 weeks old and euthanized at 8 weeks old.
Figure 2. Detection of anti-XMRV antibodies in the offspring
from XMRV-infected mice. (A) Flow cytometry data from 293T cells
is indicated as XMRV negative (2) control. XMRV-GFP virus was pre-
treated with plasma samples from infected mice (XMRV positive (+)
anti-XMRV), non-infected mice (XMRV positive (+)c o n t r o l ) ,a n d
offspring (B1, B7, and B9) at a dilution of 1:20, and then used to infect
293T cells. Numbers shown in parentheses are the percentages of
neutralization, which was calculated as the reciprocal of infectivity with
a maximum infectivity being determined by incubation of the virus with
an uninfected mouse serum. NA, not applicable. (B) XMRV proteins were
detected by Western blotting. Data from mice infected with XMRV after
8 and 24 weeks p.i. as positive controls and three offspring (B1, B7, and
B9) are shown. Sizes of expected viral proteins are indicated to the left
side of the Western blotting: envelope glycoprotein, Env (gp70), capsid,
CA (p30), transmembrane, TM (p15E), and matrix, MA (p15).
doi:10.1371/journal.pone.0029682.g002
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Blood samples were collected at 8 wk, 12 wk, 16 wk, 24 wk,
and 1 year p.i. and analyzed by VetScanHM2 Hematology System
(Abaxis). At 1 year p.i., blood chemistry was evaluated by
Comprehensive Diagnostic Profile (Abaxis).
Neutralization assay
A GFP vector pseudotyped with XMRV was used for
neutralization assay as previously reported (24). Plasma samples
were heat inactivated at 56uC for 30 min. The samples at a
dilution of 1:20 were incubated with 2.5610
4 infectious units (IU)
Figure 3. Sequence analysis of env gene from XMRV proviral DNA-positive offspring samples. (A) Nested-PCR, cloning, and sequence
analysis were performed as described previously [33]. The number of mutations in the env gene from lymph node and heart of the mouse B1 are
summarized. A total of 2751 bp and 4366 bp were sequenced from lymph node and heart, respectively. (B) Schematic representation of XMRV Env
with partial amino acid sequence of receptor binding domain (RBD) is shown. One Env isolate from heart (B1: GenBank accession no. JN987227) has
one amino acid deletion of serine at position 148 in SU as boxed in blue. Amino acids from 1 to 33, from 34 to 444, and from 445 to 645 indicate
signal peptide (SP), surface protein (SU), and transmembrane protein (TM), respectively. Variable regions (VRA, VRB, and VRC) are highlighted in gray.
(C) Protein expression of wild-type XMRV Env and XMRV Env with S148 mutation was analyzed by Western blotting. Env protein was visualized with
goat anti-MLV antibody (1:2000, ATCC). Actin (1:2000, sigma) was also detected as a loading control. Statistical analysis showed that protein
expression was not statistically significant (p=0.31). (D) Retroviral vectors pseudotyped with XMRV Env or XMRV Env with S148 mutation were
produced by transient transfection in 293T cells. The transduction titer of retrovirus pseudotyped with XMRV Env or XMRV Env with a serine mutation
is statistically significant (p=0.009). Error bars indicate 95% confidence intervals.
doi:10.1371/journal.pone.0029682.g003
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4 293T cells
(ATCC) were infected for 3 days and GFP-positive cell
populations were analyzed by flow cytometry (FACscan). GFP-
positive cell populations were gated by excluding XMRV negative
control cell population. Boxed regions show GFP-positive cells
with percentages. Viral titers were calculated as infective units per
milliliter (IU/ml) as described previously [44].
qPCR
DNA from mice tissues and blood samples were extracted by
using a PureLink genomic DNA mini kit (Invitrogen) according to
the manufacturer’s protocol. For the real-time PCR assay,
TaqMan Universal PCR Master Mix (Roche), probes (Roche)
and primers were used as described previously using ABI 7300
real-time PCR [29,33].
Detection of XMRV DNA in blood and tissue samples and
viral RNA in plasma samples
DNA from mouse blood and tissue was extracted by using
PureLink genomic DNA mini kit (Invitrogen) and viral RNA from
plasma samples was extracted by QIAamp viral RNA mini kit
(QIAGEN). cDNA from viral RNA was synthesized by RNA to
cDNA EcoDry Premix (Clontech) and qPCR was performed to
detect XMRV sequences. qPCR positive samples were further
analyzed by nested PCR with platinum Taq polymerase (Invitro-
gen). XMRV gag was PCR amplified using the outer primers 59-
ACGAGTTCGTATTCCCGGCCGCA-39 and 59-CCGCCTC-
TTCTTCATTGTTC-39 and the inner primers 59-GCCCA-
TTCTGTATCAGTTAA-39 and 59-AGAGGGTAAGGGCAG-
GGTAA-39. For the XMRV env amplification, the outer primers
59- ATGGAAAGTCCAGCGTTCTCAAA-39 and 59- ATGGG-
GACGCGGGGCCCTACATTG-39 and the inner primers 59-
AGGAGCCTCAGTACAACGTGACAG-39 and 59- TGGCG-
GGTCAGAGAGAACAGGG-39 were used. The PCR products
were then cloned into TOPO vector (Invitrogen), and the
amplified sequences were analyzed by DNADynamo (BlueTractor
Software).
Western blotting
The virus antigen was prepared by transfecting 293T cells with
pcDNA3.1 (2)/VP62. Three days p.i., supernatants were
collected, filtered through 45 mm filter and centrifuged through
20% sucrose cushion at 13,000 rpm at 4uC. They were
centrifuged at the same conditions with PBS. The virus particles
were then resuspended in Laemmli sample buffer containing b-
mercaptoethanol, and boiled at 95uC for 5 min. Protein samples
(10 ml) were subjected for SDS-PAGE with a 4–15% gradient gel
(Bio-Rad), and transferred to a polyvinylidene difluoride mem-
brane. They were stained with plasma samples at dilution of 1:100,
followed by ant-mouse IgG antibody (1:2000). Protein expression
was quantified by Image-J and the adjusted density value was
calculated by the following link: http://lukemiller.org/index.php/
2010/11/analyzing-gels-and-western-blots-with-image-j/. For sta-
tistical analysis, Student’s t-test was performed.
Production of Retrovirus vectors
Retrovirus vector was created by transfecting a MLV packaging
plasmid (0.25 mg), a green fluorescent protein (GFP) vector
plasmid (0.5 mg), and an Env-encoding plasmid (0.25 mg) using
FuGENE-6 (Roche). Three days after transfection, supernatants
were filtered through 0.45-mm filters (Millipore) and 5610
4 of
293T cells were transduced with the vectors in the presence of
polybrene (8 mg/ml). At three days post-transduction, cells were
fixed with 4% paraformaldehyde, and GFP-positive cells were
determined by flow cytometry (FACScan). Titers were calculated
as infective units per milliliter (IU/ml) as described previously
[44].
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